help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ono, T.
Right arrow Articles by Mohan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ono, T.
Right arrow Articles by Mohan, S.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 2111-2116, Copyright © 1996 by Endocrine Society


ARTICLES

Growth hormone (GH) treatment of GH-deficient children increases serum levels of insulin-like growth factors (IGFs), IGF-binding protein-3 and -5, and bone alkaline phosphatase isoenzyme

T Ono, S Kanzaki, Y Seino, DJ Baylink and S Mohan
Department of Pediatrics, Okayama University Medical School, Japan.

To investigate the contribution of the insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) to the regulation of bone growth in 10 GH-deficient Japanese children receiving recombinant GH therapy, we determined the percent increase from pretreatment levels of serum IGF-I, IGF-II, IGFBP-3, IGFBP-5, and bone-specific alkaline phosphatase isoenzyme (B-ALP). For 10 children between 6-13 yr of age, serum IGF-I and IGF-II were increased after 1 month of treatment by 53% and 7%, respectively; after 12 months of therapy, IGF levels remained elevated at 51% and 17%, respectively. Serum IGFBP-3 and IGFBP-5 were also increased after 1 month of GH therapy by 17% and 13% respectively; after 12 months of therapy, they remained elevated at 22% and 15%, respectively. After 12 months of treatment, the bone formation marker B- ALP was also elevated to 23% greater than pretreatment levels. The elevation of IGF-I induced by GH was significantly correlated with the increases in IGFBP-3 (r = 0.735; P < 0.0001) and IGFBP-5 (r = 0.795; P < 0.0001), and the elevation of B-ALP was also significantly positively correlated with the increases in IGF-I, IGF-II, IGFBP-3, and IGFBP-5 (r = 0.544, P < 0.0001; r = 0.268, P = 0.0399; r = 0.414, P = 0.0010; and r = 0.500, P < 0.0001, respectively). Our data are consistent with the anabolic effect on bone growth of GH treatment being mediated by IGF- II, IGFBP-3, and IGFBP-5 as well as by IGF-I. This is the first evidence that GH treatment increases IGF-II in GH-deficient children. This finding was probably the result of application of a valid assay that measures IGF-II without interference of IGFBPs.


This article has been cited by other articles:


Home page
ChestHome page
M. Malerba, S. Bossoni, A. Radaeli, E. Mori, S. Bonadonna, A. Giustina, and C. Tantucci
Growth Hormone Response to Growth Hormone-Releasing Hormone Is Reduced in Adult Asthmatic Patients Receiving Long-term Inhaled Corticosteroid Treatment
Chest, February 1, 2005; 127(2): 515 - 521.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. Mohan, G. Masinde, X. Li, and D. J. Baylink
Mapping Quantitative Trait Loci That Influence Serum Insulin-Like Growth Factor Binding Protein-5 Levels in F2 Mice (MRL/MpJ X SJL/J)
Endocrinology, August 1, 2003; 144(8): 3491 - 3496.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Ueland, J. Bollerslev, A. Flyvbjerg, T. B. Hansen, N. Vahl, and L. Mosekilde
Effects of 12 Months of GH Treatment on Cortical and Trabecular Bone Content of IGFs and OPG in Adults with Acquired GH Deficiency: A Double-Blind, Randomized, Placebo-Controlled Study
J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2760 - 2763.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. H. Aguiar-Oliveira, M. S. Gill, E. S. de, A. Barretto, M. R. S. Alcântara, F. Miraki-Moud, C. A. Menezes, A. H. O. Souza, C. E. Martinelli, F. A. Pereira, et al.
Effect of Severe Growth Hormone (GH) Deficiency due to a Mutation in the GH-Releasing Hormone Receptor on Insulin-Like Growth Factors (IGFs), IGF-Binding Proteins, and Ternary Complex Formation Throughout Life
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4118 - 4126.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
H. Olivecrona, A. Hilding, C. Ekström, H. Barle, B. Nyberg, C. Möller, P. J. Delhanty, R. C. Baxter, B. Angelin, T. J. Ekström, et al.
Acute and Short-Term Effects of Growth Hormone on Insulin-Like Growth Factors and Their Binding Proteins: Serum Levels and Hepatic Messenger Ribonucleic Acid Responses in Humans
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 553 - 560.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
D. R. Powell, S. K. Durham, E. D. Brewer, J. W. Frane, S. L. Watkins, R. J. Hogg, and S. Mohan
Effects of Chronic Renal Failure and Growth Hormone on Serum Levels of Insulin-Like Growth Factor-Binding Protein-4 (IGFBP-4) and IGFBP-5 in Children: A Report of the Southwest Pediatric Nephrology Study Group
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 596 - 601.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Kawai, S. Kanzaki, S. Takano-Watou, C. Tada, Y. Yamanaka, T. Miyata, M. Oka, and Y. Seino
Serum Free Insulin-Like Growth Factor I (IGF-I), Total IGF-I, and IGF-Binding Protein-3 Concentrations in Normal Children and Children with Growth Hormone Deficiency
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 82 - 89.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Ueland, J. Bollerslev, T. B. Hansen, E. N. Ebbesen, L. Mosekilde, K. Brixen, A. Flyvbjerg, and O. Djøseland
Increased Cortical Bone Content of Insulin-Like Growth Factors in Acromegalic Patients
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 123 - 127.
[Abstract] [Full Text]


Home page
PediatricsHome page
N. S. Glaser, A. C. Shirali, D. M. Styne, and K. L. Jones
Acid-base Homeostasis in Children With Growth Hormone Deficiency
Pediatrics, December 1, 1998; 102(6): 1407 - 1414.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. M. Twigg and R. C. Baxter
Insulin-like Growth Factor (IGF)-binding Protein 5 Forms an Alternative Ternary Complex with IGFs and the Acid-labile Subunit
J. Biol. Chem., March 13, 1998; 273(11): 6074 - 6079.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg
Growth Hormone and Bone
Endocr. Rev., February 1, 1998; 19(1): 55 - 79.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
G. L. Klein, S. E. Wolf, C. B. Langman, C. J. Rosen, S. Mohan, B. S. Keenan, S. Matin, C. Steffen, M. Nicolai, D. E. Sailer, et al.
Effect of Therapy with Recombinant Human Growth Hormone on Insulin-Like Growth Factor System Components and Serum Levels of Biochemical Markers of Bone Formation in Children After Severe Burn Injury
J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 21 - 24.
[Abstract] [Full Text]


Home page
Endocr. Rev.Home page
S. Rajaram, D. J. Baylink, and S. Mohan
Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions
Endocr. Rev., December 1, 1997; 18(6): 801 - 831.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society